C3GN1 | C3GN2 | C3GN3 | DDD1 | C3GN4 | DDD2 | C3GN5 | |
---|---|---|---|---|---|---|---|
native/grafta | graft | native | graft | native | graft | native | native |
Baseline SCr (mg/dl) | 1.9 | 2.3 | 2.1 | 1.5 | 3.3 | 2.1 | 0.8 |
Baseline UPCR (g/g) | 5.4 | 0.3 | 0.3 | 5.0 | 3.4 | 5.4 | 5.6 |
Baseline hematuriab (0–4) | 4 | 4 | 3 | 4 | 4 | 4 | 2 |
Therapy | pre Tx none | none | pre Tx prednisone, MMF, azathioprine | none | pre Tx cyclo- sporine A, cyclophos-phamide | none | PEX, FFP, immune-globulins, prednisone, MMF [25] |
post Tx prednisone, tacrolimus, MMF, rituximab | post Tx prednisone, tacrolimus, MMF (graft) | post Tx prednisone, tacrolimus, MMF, cyclophos-phamide, PEX [41] (graft) | |||||
Time to graft relaps (months) | 48 | – | 3 | – | de novo C3GN 135 months post Tx | – | – |
Time diagnosis to eculizumab (months) | 144 (native); 0 (graft) | 7 | 88 (native); 2 (graft) | 128 | 2 (graft) | 7 | 11 |
Treatment duration (months) | 27 | 26 | 9 | 24 | 3; 3 | 16 | 28 |
Response SCr | stable | yes | stable | stable | initially yes; recurrence no | initially stable; ultimately no | no |
Response UPCR | yes | stable | stable | initially yes; ultimately stable | initially yes; recurrence no | initially stable; ultimately no | no |
Response hematuria | stable | yes | stable | yes | stable | yes | yes |